478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)

Bibliographic Details
Title: 478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)
Authors: Inbal Barbiro, Amita Patnaik, Manish Sharma, Drew Rasco, Ryan Sullivan, Ecaterina Dumbrava, Pierre Ferre, Gini Fleming, Kyriakos Papadopoulos, Daniel Vaena, Adam ElNaggar, Adeboye Adewoye, Robina Smith, Emerson Lim
Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Publisher Information: BMJ Publishing Group, 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2051-1426
Relation: https://doaj.org/toc/2051-1426
DOI: 10.1136/jitc-2021-SITC2021.478
Access URL: https://doaj.org/article/79090e9b14894f908bab8530154d36f2
Accession Number: edsdoj.79090e9b14894f908bab8530154d36f2
Database: Directory of Open Access Journals
More Details
ISSN:20511426
DOI:10.1136/jitc-2021-SITC2021.478
Published in:Journal for ImmunoTherapy of Cancer
Language:English